Citations

Clear

511 citation(s) found for "Seth, N".

Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning
Park, Jihwan, Fan, Leon, Marzinke, Mark A., Sokoll, Lori J., Muthukumar, Alagarraju, Murphy, Sabina A., Sabatine, Marc S., Gurudu, Rachana, Meeusen, Jeff W., Martin, Seth S., Marzinke, Mark A. , Sokoll, Lori J. , Muthukumar, Alagarraju , Murphy, Sabina A. , Sabatine, Marc S. , Gurudu, Rachana, Meeusen, Jeffrey W. , Martin, Seth S.

Mayo Clinic

JAMA Cardiology | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2314 | PMID 42455545 Get It

Importance Although the Martin-Hopkins equation is widely validated and used to estimate low-density lipoprotein cholesterol (LDL-C) for clinical care, a simplified equation could streamline implementation and enable broader adoption. Objective To develop a simplified machine learning–based alternative to the Martin-Hopkins equation using multivariate adaptive regression splines (LDL-C–MH-MARS) and compare its performance with the Friedewald (LDL-C–F), Sampson–National Institutes of Health (LDL-C–S), Modified Sampson (LDL-C–MS), and Martin-Hopkins (LDL-C–MH) equations. Design, Setting, and Participants The Very Large Database of Lipids is a cross-sectional database of clinical lipid measurements from a population-representative convenience sample of adult and pediatric patients. Lipid measurements were performed by Vertical Auto Profile ultracentrifugation between October 1, 2015, and June 30, 2019. The study included patients with complete lipid panel data who were randomly assigned to a training set and a test set. External validation against preparative ultracentrifugation-based LDL-C measurements was performed in reference laboratory datasets from the Mayo Clinic (broad LDL-C concentrations) and the Further Cardiovascular Outcomes Research With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial (observations from patients with low LDL-C concentrations while taking evolocumab). Study data were analyzed from January to October 2025. Exposures LDL-C–F, LDL-C–S, LDL-C–MS, LDL-C–MH, and LDL-C–MH-MARS equations. Main Outcomes and Measures Accuracy of estimated vs ultracentrifugation-measured LDL-C concentration based on bias, root mean square error (RMSE), and concordance by guideline-based categories. Results The study included 4 939 528 patients (mean [SD] age, 56 [16] years; 2 635 486 female [53%]) with complete lipid panel data who were randomly assigned to a training set (n = 3 292 889) and a test set (n = 1 646 639). LDL-C–MH-MARS equation demonstrated a very low median (IQR) bias of −0.1 (−2.1 to 1.8) mg/dL (to convert to millimoles per liter, multiply by 0.0259), comparable with LDL-C–MH. The median (IQR) difference between the MARS and original Martin-Hopkins equations (ie, LDL-C–MH-MARS – LDL-C–MH) was −0.5 (−1.2 to 0) mg/dL, further suggesting comparability between the 2 methods. The RMSE was smallest for LDL-C–MH-MARS (4.7 mg/dL) and LDL-C–MH (4.9 mg/dL), followed by LDL-C–S (5.8 mg/dL), LDL-C-MS (6.0 mg/dL), and LDL-C–F (7.2 mg/dL). The proportion of patients correctly classified according to clinical categories was nearly identical for LDL-C–MH-MARS (89.7%) and LDL-C–MH (89.6%) but lower for LDL-C–S (86.3%), LDL-C–MS (84.7%), and LDL-C–F (83.1%). The LDL-C–MH-MARS, LDL-C–MH, LDL-C–MS, LDL-C–S, and LDL-C–F equations underestimated LDL-C concentration in 16%, 17%, 28%, 39%, and 60%, respectively, when classifying LDL-C less than 70 mg/dL in patients with triglyceride concentrations of 200 to 399 mg/dL (to convert to millimoles per liter, multiply by 0.0113). The patterns of results were similar in external validation datasets, with the LDL-C–MH-MARS and LDL-C–MH equations demonstrating the highest accuracy. Conclusions and Relevance Study results suggest that the new machine learning–based LDL-C equation provided results comparable with those of the original Martin-Hopkins method while simplifying implementation to a single equation.
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology
Kamran, Sophia C. , Borges, Monica, Michalski, Jeff M. , Lee, W. Robert , Sandler, Howard M. , Crook, Juanita , Pollack, Alan , Hurwitz, Mark , Valicenti, Richard K., Bruner, Deborah Watkins , Lukka, Himanshu, Jones, Christopher U. , Roach, Mack , Lawton, Colleen, PISANSKY, T, Spratt, Daniel, VAPIWALA, N, Miyamoto, David T. , Mouw, Kent, Vyfhuis, Melissa A.L. , Le, Quynh‐Thu , Willers, Henning , Franklin, Huang, Bahary, Jean-Paul , Helou, Joelle, Pugh, Stephanie L. , Wenzel, Jennifer , Michalski, Jeff M , Pisansky, Thomas M. , Efstathiou, Jason A , Miyamoto, David , Vyfhuis, Melissa , Le, Quynh-Thu , Van Allen, Eliezer M , Bahary, Jean-Paul , Wenzel, Jennifer , Tran, Phuoc T , Bruner, Deborah , Sandler, Howard M , Valicenti, Richard K., Lukka, Himanshu, Rosenthal, Seth A. , Spratt, Daniel E. , Vapiwala, Neha , Efstathiou, Jason A. , Helou, Joelle

Mayo Clinic

JCO Precision Oncology | July 8, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1200/po-26-00158 | PMID 42418740 Get It

PURPOSE Precision medicine has revolutionized oncology; however, tumor biomarkers are not reflective of the heterogeneous cancer population. We evaluated NRG Oncology prostate cancer (PCa) clinical trials for demographic differences among patients with optional biospecimen collection (BC) consent and biospecimen submission (BSub). METHODS Data from 19 NRG PCa clinical trials closed before 2015 were analyzed. Patients who consented to BC and completed BSub were evaluated by race, ethnicity, median income, area deprivation index (ADI; categorized as highest v lowest three quartiles), age at enrollment, site, and year of enrollment. T/chi-square tests were used for continuous/categorical variables, respectively, followed by logistic regression. RESULTS Of the 15,648 randomized patients eligible for BC, 11,796 (75%) had specimens submitted. In all, 4,598 (82.2%) of 5,597 eligible patients consented for optional BC in nine clinical trials with a separate BC consent process (consent rates by race/ethnicity: 74.1% Black, 72.8% Hispanic/Latino, 83.8% White). A smaller proportion of Black and Hispanic/Latino patients consented to optional BC compared with those who did not (12.1% v 19.5% Black, P < .0001; 3.5% v 5.8% Hispanic, P = .0006). In univariable logistic regression models, high ADI (more socioeconomic disadvantage) was associated with a decreased likelihood for optional BC consent (odds ratio [OR], 0.67 [95% CI, 0.55 to 0.82]; P = .02), but not a decreased likelihood for BSub (OR, 0.74 [95% CI, 0.53 to 1.04]; P = .08). Multivariable models demonstrated that Black/Hispanic/Latino patients were less likely to consent to optional BC, and Black patients were less likely to have BSub ( P < .05 for all). CONCLUSION White/non-Hispanic patients and those with less socioeconomic disadvantage were more likely to consent to optional BC, whereas Black patients were less likely to have BSub. Targeted solutions are needed to improve biorepository representation so that precision medicine approaches better reflect the cancer population.
Developmental genetic determinants of the human cerebrospinal fluid–ventricular system
Allington, Garrett , Dennis, Evan , Li, Qiang , McGee, Stephen , Mekbib, Kedous Y., Hatada, Izuho , Weston, Matthew C. , Shore, Amy N., Cullen, Erin R. , Singh, Amrita , Miyagishima, Danielle , Kiziltug, Emre, Hale, Andrew T. , Fan, Baojian , Nelson-Williams, Carol, Moreno-De-Luca, Andrés , Kasper, Ekkehard M. , Smith, H M, Davalan, William C., Kundishora, Adam J. , Luikart, Bryan W. , Haider, Shozeb , Alper, Seth L. , Lifton, Richard P. , Jin, Sheng Chih , Kahle, Kristopher T. , Weston, Matthew C , Shore, Amy N , Cullen, Erin R , Miyagishima, Danielle , Hale, Andrew T , Fan, Baojian , Moreno-de-Luca, Andrés , Kasper, Ekkehard M , Kundishora, Adam J , Luikart, Bryan W , Haider, Shozeb , Alper, Seth L , Lifton, Richard P , Jin, Sheng Chih , Kahle, Kristopher T , Mehta, Neel H. , Mekbib, Kedous Y. , DeSpenza, Tyrone , Duy, Phan Q. , Nelson‐Williams, Carol

Mayo Clinic

Science Translational Medicine | July 8, 2026 | Volume: 18 | Issue: 857 | Pages: No page available

10.1126/scitranslmed.aec4386 | PMID 42418557 Get It

Primary enlargement of the cerebrospinal fluid (CSF)–filled brain ventricles, known as congenital cerebral ventriculomegaly (CCV), is a hallmark of congenital hydrocephalus. CCV is also enigmatically but frequently associated with autism and other neurodevelopmental disorders. To gain insight into the developmental genetic regulation of the human CSF-ventricular system, we conducted an integrated, multiomic study of about 2700 trio-based exomes from patients with primary CCV. We found that about 25% of cases were associated with rare, damaging de novo variants in mutation-intolerant genes, many of which are linked to other dominant Mendelian disorders. Thirty-five exome-wide significant CCV genes and dozens of other high-confidence CCV genes converged on pathways involved in ATP-dependent Brahma-related gene 1/Brahma-associated factor chromatin remodeling, histone H3 lysine 4 methylation, and phosphoinositide 3-kinase signaling. Knockout of selected CCV genes in mouse models supported that de novo variants in CCV genes caused ventriculomegaly by impairing both CSF dynamics and cortical cytoarchitecture through dysregulation of neuroprogenitor cell growth and maturation in the ventricular and subventricular zones. These findings indicated that genetic and epigenetic programs coordinate the “hand-in-glove” development of the CSF-ventricular system with that of the cerebral cortex and establish a genetic connection between CCV and neurodevelopmental disorders, potentially explaining why some patients with hydrocephalus continue to exhibit CCV and neurodevelopmental disorders despite CSF shunting. We suggest that combined brain imaging and whole-exome sequencing could enable early detection of, and intervention for, autism and other neurodevelopmental disorders.
Rosai-Dorfman Disease: Imaging and Updates
Shaikh, Mohd Javed Saifullah, Aswani, N, Marcelino, Leonardo Gomes , Driver, Zubin Vicky , Islam, Galib Mirza Nasirul, Kandemirli, Sedat Giray , Kawashima, Akira , Holman, Carol , Diamond, Eli , Sekhar, Aarti , Shah, Amar S , Shaikh, Mohd Javed Saifullah , Aswani, Nishant , Gomes Marcelino, Leonardo , Driver, Zubin Vicky , Nasirul Islam, Galib Mirza , Kandemirli, Sedat , Kawashima, Akira , Homan, Carol J , Itani, Malak , Sekhar, Aarti , Aswani, Yashant , Shah, Amar , Diamond, Eli, Itani, Malak

Mayo Clinic

RadioGraphics | June 25, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1148/rg.250179 | PMID 42348448 Get It

Although Rosai-Dorfman disease has nonspecific imaging features, imaging remains essential for delineating disease extent, predicting prognosis, and assessing treatment response once the diagnosis is established through integrated clinical, imaging, and histopathologic evaluation.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
GLUT9b- and ABCG2-mediated collecting duct urate transport uncovers a vasopressin-independent mechanism of renal water reabsorption
Hadla, Mohamad , Mardirossian, Jean Marc , Bichet, Daniel, Borghol, Abdul Hamid , Abboud, Georges, Ghanem, Ahmad , Chini, Eduardo N., Harris, Peter, Alper, Seth L., Vallon, Volker , Chini, Eduardo, Hadla, Mohamad , Vallon, Volker , Bichet, Daniel Georges , Abboud, Georges , Chini, Eduardo N. , Harris, Peter C. , Torres, Vicente E. , Alper, Seth L. , Chebib, Fouad T.

Mayo Clinic

Journal of Clinical Investigation | June 16, 2026 | Volume: 136 | Issue: 14 | Pages: No page available

10.1172/jci197021 | PMID 42298327 Get It

Renal water reabsorption is classically regulated by vasopressin V2 receptor (V2R) signaling through cyclic AMP and protein kinase A, driving apical accumulation of aquaporin-2 (AQP2). However, collecting duct water handling is also modulated by vasopressin-independent mechanisms. Here, we examined intracellular soluble urate as a vasopressin-independent regulator of AQP2 trafficking. Intracellular urate accumulation in collecting duct cells was mediated by enhanced apical urate uptake via GLUT9b and reduced apical urate efflux through ABCG2, triggering phosphodiesterase-4 activation, reduced cAMP, and downstream AMP-activated protein kinase (AMPK) activation. The resulting AQP2 accumulation at the apical membrane was independent of V2R signaling, required ongoing endocytosis, and was associated with features of postendocytic apical trafficking of internalized AQP2. In vivo ABCG2 inhibition with probenecid increased apical AQP2 abundance and markedly attenuated tolvaptan-induced polyuria in both wild-type and Pkd1 RC/RC autosomal dominant polycystic kidney disease (ADPKD) mice in a uricase-independent manner while preserving tolvaptan’s ADPKD-modifying efficacy. In a phase II trial with tolvaptan-treated patients with ADPKD, probenecid reduced urine volume and nocturia frequency. Together, these findings support a vasopressin-independent urate/AMPK/AQP2 pathway that regulates renal water handling and, in a preclinical ADPKD model, can uncouple cyst growth attenuation from the dose-limiting aquaretic effects of V2R antagonism.
Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms
Lee, Alyssa M., Seth, N, Tam, Wayne , Jiang, Liuyan, Abeykoon, Jithma P., King, Rebecca L., Reichard, Kaaren K., Go, Ronald S., Goyal, G., Rech, Karen L., Ravindran, Aishwarya , Network, on behalf of the Histio-care, Yi, Dongni , Ravindran, Aishwarya , Abeykoon, Jithma P. , King, Rebecca L., Reichard, Kaaren K. , Go, Ronald S. , Goyal, Gaurav, Morlote, Diana M. , Rech, Karen L.

Mayo Clinic

American Journal of Surgical Pathology | June 15, 2026 | Volume: 50 | Issue: 9 | Pages: 1067-1075

10.1097/pas.0000000000002570 | PMID 42290298 Get It

Myeloid sarcoma (MS) is a tumor mass involving any extramedullary site composed of myeloid-lineage blasts with myeloid, myelomonocytic, or monocytic differentiation. Distinguishing MS from malignant histiocytic neoplasms (MHNs) is diagnostically challenging due to morphologic and immunophenotypic overlap, particularly for MS with monocytic differentiation, which can mimic MHNs, especially the subtypes of histiocytic sarcoma and interdigitating dendritic cell sarcoma, leading to potential misdiagnosis and inappropriate management. Cyclin D1 overexpression is implicated in MHNs, but its utility in differentiating these entities has not been systematically characterized. We evaluated cyclin D1 immunostaining in 43 MS cases and 30 MHNs. The median age at MS diagnosis was 59 years (range: 0.1 to 90), while the median age at MHN diagnosis was 62 years (range: 9 to 90), with heterogeneous sites of involvement. Cyclin D1 evaluation showed 100% MHNs with strong cyclin D1 positivity in ≥50% tumor cells, compared with 7% MS with weak-to-intermediate positivity in a minor subset of tumor cells. Additional immunohistochemical evaluation showed no difference in PU.1 expression in MHNs (93%) versus MS (84%) but demonstrated a higher proportion of OCT2-positivity in MHNs over MS (52% vs. 23%, P <0.05). Our study demonstrates a high sensitivity (100%) and specificity (93%) in utilizing cyclin D1 to distinguish MHNs (mature phenotype) from MS (immature phenotype) in diagnostic practice. It is particularly valuable in challenging scenarios of MS with the absence of immature/myeloid lineage-defining markers (MPO, CD34, or CD117) and provides a cost-effective tool to resolve this diagnostic pitfall, ensuring an accurate subclassification.
Trends in Delays to Immunotherapy in Patients with Autoimmune Encephalitis (P9-1.010)
Levinsky, Justin, Sladoje, Lana, Lim-Fat, Mary Jane, Muccilli, Alexandra, Day, Gregory, Lapointe, Sarah, Climans, Seth, Wennberg, Richard, Tang-Wai, David, Hébert, Julien , Levinsky, Justin T. , Lim-Fat, Mary Jane, Muccilli, Alexandra, Day, Gregory S. , Lapointe, Sarah, Climans, Seth , Wennberg, Richard , Tang‐Wai, David F.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215787 Get It

Incidence and Outcomes of Refractory Septic Shock per Consensus Clinical Criteria: A Multicohort Retrospective Study
Bauer, Seth R. , Wieruszewski, P M, Khanna, Ashish K., Leone, Marc, Barreto, E, DUGAR, SIDDHARTH, Mourany, Lyla, Reddy, Anita J, Tarabichi, Yasir, Wang, X, Vachharajani, Vidula, Bauer, Seth R , Wieruszewski, Patrick M. , Khanna, Ashish K. , Léone, Marc , Frazee, Erin N. , Dugar, Siddharth , Sacha, Gretchen , Mourany, Lyla, Gunsalus, Paul R. , Milinovich, Alex , Kane‐Gill, Sandra L. , Tarabichi, Yasir , Dalton, Jarrod E. , Vachharajani, Vidula

Mayo Clinic

Critical Care Medicine | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ccm.0000000000007234 | PMID 42240423 Get It

Objectives: Consensus clinical criteria for refractory septic shock were recently developed, but the incidence and outcomes with these criteria are unknown. There were two aims: 1) to describe the incidence of refractory septic shock and 2) to assess outcomes of patients with septic shock meeting refractory septic shock criteria compared with those who did not. Design: Multicohort, retrospective study. For aim 1, a descriptive epidemiologic study was designed to ascertain the cumulative incidence of refractory septic shock in patients with septic shock. For aim 2, a cohort study was conducted to compare hospital mortality between patients meeting refractory septic shock clinical criteria compared with those who did not. Setting: Large U.S. health system from 2012 to 2024. Patients: Adults (age ≥ 18 yr) meeting both Centers for Disease Control and Prevention Adult Sepsis Event and Sepsis-3 clinical criteria for septic shock. Patients with missing hospital discharge disposition and incomplete vasopressor dosage information were excluded. Interventions: None. Measurements and Main Results: Clinical criteria for refractory septic shock were operationalized as concomitant occurrence of norepinephrine (base) equivalent greater than 0.5 µg/kg/min and lactate greater than 2 mmol/L. Risk-adjusted hospital mortality was assessed with a generalized linear mixed-effects model with a random effect for hospital and fixed effects for age, sex, Elixhauser Comorbidity Index, and Sequential Organ Failure Assessment (original description, without cardiovascular component). Of 35,914 patients assessed, 15,732 patients with septic shock were included. Refractory septic shock occurred in 3423 patients (21.8%), with a cumulative incidence of 218 cases (95% CI, 211–224) per 1000 patients with septic shock. Hospital mortality with refractory septic shock was 64.4%, and risk-adjusted hospital mortality odds were 4.87-fold higher (95% CI, 4.46–5.31) compared with patients without refractory septic shock. Conclusions: Clinical criteria for refractory septic shock were fulfilled in about one in five patients with septic shock and associated with substantially higher mortality.